HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

ghted that marketing authorisation for VELCADE has been granted, as it is the first major advance for patients with multiple myeloma in more than a decade, and marks the company's commitment to Oncology." said Ken Watters, European Medical Director, Ortho Biotech.

"The approval of VELCADE today brings renewed hope to thousands of European multiple myeloma patients and their families" said Eric Low, Executive Director, International Myeloma Foundation (UK). "The multiple myeloma advocacy community has campaigned tirelessly over the years for cutting edge treatments such as VELCADE to be made available to patients, this is a very proud day", he continued.

The findings of a pre-specified interim analysis from an ongoing phase III trial which compared VELCADE to dexamethasone in refractory multiple myeloma patients found a statistically significant improvement in time to disease progression the primary endpoint of the trial in patients receiving VELCADE compared to patients receiving high-dose dexamethasone. Patients in the control arm of the trial were given the opportunity to switch to VELCADE as soon as possible based on an interim analysis that found a statistically significant improvement in TTP in patients receiving VELCADE compared to patients receiving dexamethasone.

VELCADE has a generally predictable, manageable safety profile (with appropriate monitoring and if necessary, dose modification). VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or mannitol. There are approximately 50 ongoing clinical trials (in Europe and the US) investigating the potential of VELCADE in all stages of multiple myeloma and other cancers.

A single licence has been granted to market VELCADE in the 15 member states of the EU, plus Norway and Iceland. In addition it will be available in the 10 accession countries.

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Ph
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:4/19/2015)... 2015 Carinsurancehints.com has released a new blog ... claim auto insurance benefits . , Drivers who ... all the necessary information for claiming auto insurance benefits. Exchanging ... plan to cover most of the damages. The newly released ... an accident. , Drivers can compare online rates and ...
(Date:4/19/2015)... April 19, 2015 The American Institute ... with PROSHRED Security (“PROSHRED”) to host its second annual, ... shred their personal documents in order to raise funds ... , The June 6th event is being held at ... 2pm local time. The time will vary at select ...
(Date:4/19/2015)... HealthPostures, LLC , a leading ... exhibit it’s pioneering ergonomics products at the Wisconsin Safety ... Council Professional Development Conference and Expo . The products, ... used in volume by call centers, educational organizations, retailers, ... clamp to a desk, the TaskMate Go 6350 and ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post explaining ... Spring. , Spring can be a great season ... sure they compare the newest policies before deciding on ... about Spring car insurance offers by reading the newly ... becoming more and more popular. Many insurance brokerage websites ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post ... . , Clients can review important auto insurance ... environment provides important advantages for clients who need affordable ... do not have coverage for their vehicles can purchase ... or hour. Many agencies offer important discounts and drivers ...
Breaking Medicine News(10 mins):Health News:An Online Guide About Claiming Auto Insurance Benefits After an Accident 2Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2
(Date:4/17/2015)... - The issue: In consultation ... lot (lot 710535) of Clavulin-400 (70mL) after receiving a complaint ... in one bottle of the  product. No other lots of ... Clavulin-400 is an oral antibiotic used in adults and children ... Clavulin-400 comes as a powder in bottles and is mixed ...
(Date:4/17/2015)... , April 17, 2015 Contego ... Integrated Embolic Protection™ filter platform for angioplasty balloon ... a $5.6 million Series B financing round led ... firm with a focus on medical devices, biopharmaceuticals, ... round also included Mountain Group Partners, Lookout Capital ...
(Date:4/17/2015)... April 17, 2015  Regulatory leaders in the pharmaceutical ... discussion draft called "21 st Century Cures." ... be taken up by Congress soon and if enacted ... device products are developed and marketed in ... companies have begun to consider how the proposed changes ...
Breaking Medicine Technology:Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle 2Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 321st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2
Cached News: